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Behçet's  disease  (BD)  is  a  chronic  relapsing  multisystem  disease  characterized  by  oral  ulceration,  genital  ulceration  and 
ocular  lesions.  Gastrointestinal  involvement  is  rare,  often  difficult  to  treat  and  associated  with  a  high  mortality  rate.  We 
treated  a  47-year-old  Korean  man  with  BD  who  had  a  recurrent  intestinal  ulcer  with  tumor  necrosis  factor  α antibody 
(infliximab);  he  initially  underwent  right  hemicolectomy  due  to  uncontrolled  intestinal  bleeding.  For  patients  with  intestinal  BD 
who  fail  to  respond  to  conventional  treatment,  infliximab  may  be  a  safe  and  effective  new  therapeutic  option. 
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INTRODUCTION
Behçet's  disease  (BD)  was  first  described  by  Behçet  in  1937 
as  a  chronic  recurrent  disease  characterized  by  recurrent  oral 
ulceration,  genital  ulceration  and  ocular  involvement
1),
  additional 
involvement  of  many  other  organs  has  been  reported  including: 
joints,  skin,  blood  vessels,  the  nervous  system  and  gastrointe-
stinal  tract
2).  Reports  on  invasion  into  the  gastrointestinal  tract 
vary  depending  on  country,  however,  it  has  been  reported  to  be 
present  in  three  to  60%  of  BD  patients
3).  For  these  patients, 
medical  treatment  is  the  primary  approach  to  therapy,  however, 
additional  surgical  treatment  is  necessary  for  cases  with 
complications  such  as,  perforation,  intractable  pain  and 
hemorrhage.  However,  lesions  frequently  recur  after  surgical 
treatment  and  the  incidence  of  more  than  one  surgical 
procedure  is  high;  such  cases  may  be  untreatable  and  lead  to 
death.  Recently,  cases  of  BD  with  gastrointestinal  involvement 
have  been  treated  with  tumor  necrosis  factor  alpha  (TNF-α) 
antibody  (Infliximab)
4, 5),  however,  there  is  no  prior  case  of  such 
treatment  reported  in  Korea.  We  treated  a  patient  with  recurrent 
intestinal  ulcer  who  underwent  right  hemicolectomy  due  to 
uncontrolled  intestinal  bleeding  with  infliximab.  The  case  is 
described  in  this  report  and  the  medical  literature  reviewed.
CASE REPORT
A  47  years  old  male  patient  was  admitted  to  the  hospital  due 
to  severe  abdominal  pain  for  five  days.  The  past  medical  history 
was  significant  for  recurrent  oral  and  genital  ulceration  over  the 
past  20  years.  He  underwent  right  hemicolectomy  due  to 
uncontrolled  intestinal  bleeding  caused  by  intestinal  Behçet's 
ulceration  10  years  previously.  Subsequently,  he  was  treated  by 
conventional  medical  therapy  including  corticosteroids,  sulfasala-
zine  and  azathioprine.  However,  intestinal  Behçet's  ulceration 
recurred  at  the  anastomosis  site  and  the  patient  required 
several  subsequent  hospitalizations  due  to  repeated  abdominal 
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Figure  1.  CT  scan  shows  a  suspicious  large  deep  ulcer  with 
gastrointestinal  wall  thickening  at  the  right  hemicolectomy  site  but 
no  obstruction  or  fistula.
 
Figure 2. (A, B) Colonoscopy shows the right hemicolectomy and a well demarcated single large ulcer with a clear ulcer bed at the stomal site.
an  acutely  ill  patient  with  a  blood  pressure  of  120/70  mmHg,  a 
pulse  rate  of  94  times/min,  a  respiratory  rate  of  24  times/min 
and  a  temperature  of  38.5℃.  The  abdomen  was  flat  with  mild 
tenderness;  the  bowel  sounds  were  normal.
The  laboratory  test  results  showed  a  white  blood  cell  count, 
540/mm
3;  hemoglobin,  7.2  g/dL;  hematocrit,  28%;  platelet  count, 
47,000/mm
3;  total  protein,  5.7  g/dL;  and  erythrocyte  sedimentation 
rate  (ESR)  was  increased  to  60  mm/H  and  C-reactive  protein 
(CRP)  was  increased  to  70  mg/L.  The  Crohn's  Disease  Activity 
Index  (CDAI)
6)  at  the  time  of  admission  was  183  and  the 
Harvey-Bradshaw  Index  (HBI)
7)  was  10.  The  computed 
tomography  showed  a  suspicious  large  deep  ulcer  with  bowel 
wall  thickening  at  the  right  hemicolectomy  site  but  no  obstruction 
or  fistula  was  observed  (Figure  1).  A  colonoscopy  showed  the 
right  hemicolectomy  and  a  well  demarcated  large  deep  ulcer 
with  a  clear  ulcer  bed  at  the  stomal  site  (Figure  2).  Colonic 
biopsies  showed  ulceration  with  necrotic  fibrin  debris,  an 
inflammatory  infiltrate  with  neutrophils  predominating  but  no 
granuloma  (Figure  3).  The  azathioprine  was  discontinued  due  to 
hematological  side  effects.  Because  of  the  uncontrolled 
continuous  abdominal  pain,  infliximab  (5  mg/kg)  was  started. 
There  were  no  observed  side  effects  from  the  infliximab;  two 
weeks  after  the  treatment  was  started,  the  symptoms  improved 
dramatically.  After  one  month,  the  laboratory  testing  showed  a 
white  blood  cell  count,  4,470/mm
3;  hemoglobin,  12.3  g/dL; 
hematocrit,  36.8%  and  a  platelet  count,  168,000/mm
3.  The  ESR 
and  CRP  were  decreased  to  11  mm/H  and  6.7  mg/L, 
respectively  and  the  CDAI  and  HBI  were  decreased  to  88  and 
2,  respectively.  Follow  up  colonoscopy  showed  a  well 
demarcated  marginal  ulcer  with  granulation  tissue  at  the  stomal 
site,  however,  the  ulcer  size  was  decreased  compared  to  the 
prior  study  (Figure  4).  A  second  infliximab  (5  mg/kg)  treatment 
was  administered  one  month  after  the  first.  The  symptoms 
continued  to  improve  and  the  abdominal  pain  resolved 
completely  four  months  after  the  second  injection  of  infliximab. 
The  CRP  and  ESR  were  maintained  in  the  normal  range  and 
the  value  of  CDAI  and  HBI  continued  to  decrease.  The  patient 
was  entirely  asymptomatic  at  the  12  month  follow  up. 
DISCUSSION
When  intestinal  ulceration  occurs  in  patients  with  BD  it  is 
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Figure 3. The colonic biopsies show ulceration with necrotic fibrin 
debris,  inflammatory  infiltrate  with  predominant  neutrophils  and 
granulation  tissue  infiltrated  into  mononuclear  leukocytes 
(Hematoxylin  and  eosion  stain,  original  magnification  ×40).
 
Figure  4.  (A,  B)  Follow  up  colonoscopy  shows decreased  size of  the punched  out  ulcer  with  granulation  tissue at  the anastomosis  site 
compared  to  the  prior  study.
found  predominately  in  the  ileocecal  region,  however,  ulcers 
may  be  found  throughout  the  entire  colon.  Colonoscopy  findings 
usually  show  deep  punched  out  ulcerations  with  nodular 
margins  and  converging  folds;  the  histological  findings  show  a 
non  specific  inflammation.  Intestinal  BD  may  be  associated  with 
a  significant  morbidity  and  mortality  which  results  from  the  high 
complication  rate
8, 9). 
Although  the  exact  pathogenesis  of  BD  is  not  completely 
understood,  it  has  been  suggested  that  the  disease  is  due  to  an 
abnormal  immune  response  to  environmental  factors  such  as 
microbial  agents  in  genetically  susceptible  individuals
10).  The 
presence  of  autoantibodies,  a  decrease  in  the  T4/T8  ratio  and 
an  increased  number  of  circulating  natural  killer  cells  and  γδ+ 
T  cells  also  suggest  an  autoimmune  etiology  of  disease
10, 11).  In 
patients  with  active  BD  an  increase  of  TNF  in  the  blood  and  an 
increase  of  γδ+  T  cells  producing  TNF  have  been  observed
12). 
Improvement  of  symptoms  has  been  reported  after  the 
administration  of  TNF  blockers  in  patients  unresponsive  to 
conventional  therapy
13).  Therefore,  TNF  has  been  considered  to 
play  an  important  role  in  the  inflammation  observed  in  BD 
patients  and  this  may  account  for  the  response  to  infliximab. 
Treatment  for  patients  with  intestinal  BD  consists  of  medical  and 
surgical  therapy.  Conventional  medical  therapeutic  options 
include:  corticosteroids,  mesalamine,  thalidomide,  bowel  rest, 
total  parenteral  nutrition  and  immunosuppressive  agents  such 
as  azathioprine
2).  However,  surgery  is  generally  required  due  to 
resistance  to  medications,  frequent  recurrence  of  lesions  and 
complications  such  as  intestinal  perforation  and  fistula  formation. 
According  to  Cha  et  al.
14),  the  rate  of  surgery  over  five  years 
has  been  reported  to  be  approximately  47%.  Recurrent  ulcers 
after  surgery  are  commonly  found  near  the  anastomosis  site,  as 
in  this  case;  the  ulcers  appear  as  deep  multiple  aphthous  ulcers 
or  as  cutaneous  intestinal  fistula.  When  these  ulcers  are 
present,  the  recurrence  rate  has  been  reported  to  be  as  high  as 
40～80%
15). 
In  our  case,  10  years  prior  to  the  admission,  the  patient  meet 
the  criteria  for  the  diagnosis  of  BD  recommended  by 
International  Study  Group  for  Behçet's  disease
16).  Based  on 
repeated  oral  and  genital  ulceration  as  well  as  a  positive 
pathergy  test,  severe  abdominal  pain  and  uncontrolled  intestinal 
bleeding,  the  patient  was  diagnosed  with  intestinal  BD  and 
underwent  a  right  hemicolectomy.  Despite  conventional  medical 
treatment,  he  had  recurrent  intestinal  ulceration  and  intractable 
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abdominal  pain,  therefore,  another  treatment  modality  was 
required.  Infliximab  has  been  effective  for  induction  and 
maintenance  treatment  in  patients  with  BD  and  has  been 
particularly  successful  for  treatment  of  cases  with  severe 
mucocutaneous
17),  gastrointestinal
4, 5)  and  ocular
18)  manifestations 
of  BD.  For  patients  with  intestinal  BD,  in  cases  treated  with 
infliximab,  the  standard  dose  of  infliximab  has  not  yet  been 
established,  however,  treatment  according  to  the  dose  and 
protocol  used  for  Crohn's  disease
5)  or  based  on  the  symptoms 
of  the  patient
4, 19)  have  been  reported.
The  disease  activity  of  the  patient  was  evaluated  before  and 
after  treatment,  the  CDAI  and  HBI  were  used  for  Behçet's 
disease  because  there  is  no  activity  index  established  to  date. 
In  our  case,  infliximab  (5  mg/kg)  was  administered  at  0  and  4 
weeks  and  symptomatic  complete  remission  was  observed  at 
the  12  month  follow  up,  in  addition,  endoscopic  improvement 
was  also  observed.  A  third  infusion  of  infliximab  will  be 
considered  for  future  symptoms  or  endoscopic  findings.  This 
case  illustrates  that  for  patients  with  BD  who  fail  to  respond  to 
conventional  treatment,  infliximab  may  be  a  safe  and  effective 
new  therapeutic  option.  The  long  term  safety  and  efficacy  of 
infliximab  therapy  requires  further  study. 
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